TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT

TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT

Objective: to study the time course of rituximab therapy-induced changes in the synovial fluid levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), interleukins (IL) 1β and 6, and tumor necrosis factor-α (TNF-α) in patients with rheumatoid arthritis (RA). Res...

Full description

Bibliographic Details
Main Authors: A V Bezgin, L A Knyazeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2011-08-01
Series:Научно-практическая ревматология
Subjects:
proinflammatory cytokines
rituximab
rheumatoid arthritis
Online Access:https://rsp.mediar-press.net/rsp/article/view/345
id doaj-308c9e1662064202bd835d2bfc76b858
record_format Article
spelling doaj-308c9e1662064202bd835d2bfc76b8582021-08-02T09:05:42ZrusIMA-PRESS LLCНаучно-практическая ревматология1995-44841995-44922011-08-01494444610.14412/1995-4484-2011-61285TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENTA V BezginL A KnyazevaObjective: to study the time course of rituximab therapy-induced changes in the synovial fluid levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), interleukins (IL) 1β and 6, and tumor necrosis factor-α (TNF-α) in patients with rheumatoid arthritis (RA). Results and discussion. The synovial fluid levels of IL-1ß, IL-6, TNF-α, OPG, and RANKL were studied in 54 RA patients who were seropositive for rheumatoid factor and cyclic citrullinated peptide. Differences were found in the levels of the study cytokines in patients with a varying duration of the disease. Conclusion. Rituximab was observed to be highly effective in correcting cytokine parameters in early RA.https://rsp.mediar-press.net/rsp/article/view/345proinflammatory cytokinesrituximabrheumatoid arthritis
collection DOAJ
language Russian
format Article
sources DOAJ
author A V Bezgin
L A Knyazeva
spellingShingle A V Bezgin
L A Knyazeva
TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
Научно-практическая ревматология
proinflammatory cytokines
rituximab
rheumatoid arthritis
author_facet A V Bezgin
L A Knyazeva
author_sort A V Bezgin
title TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
title_short TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
title_full TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
title_fullStr TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
title_full_unstemmed TIME COURSE OF CHANGES IN THE SYNOVIAL FLUID LEVELS OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ATHRITIS PATIENTS DURING RITUXIMAB TREATMENT
title_sort time course of changes in the synovial fluid levels of proinflammatory cytokines in rheumatoid athritis patients during rituximab treatment
publisher IMA-PRESS LLC
series Научно-практическая ревматология
issn 1995-4484
1995-4492
publishDate 2011-08-01
description Objective: to study the time course of rituximab therapy-induced changes in the synovial fluid levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), interleukins (IL) 1β and 6, and tumor necrosis factor-α (TNF-α) in patients with rheumatoid arthritis (RA). Results and discussion. The synovial fluid levels of IL-1ß, IL-6, TNF-α, OPG, and RANKL were studied in 54 RA patients who were seropositive for rheumatoid factor and cyclic citrullinated peptide. Differences were found in the levels of the study cytokines in patients with a varying duration of the disease. Conclusion. Rituximab was observed to be highly effective in correcting cytokine parameters in early RA.
topic proinflammatory cytokines
rituximab
rheumatoid arthritis
url https://rsp.mediar-press.net/rsp/article/view/345
work_keys_str_mv AT avbezgin timecourseofchangesinthesynovialfluidlevelsofproinflammatorycytokinesinrheumatoidathritispatientsduringrituximabtreatment
AT laknyazeva timecourseofchangesinthesynovialfluidlevelsofproinflammatorycytokinesinrheumatoidathritispatientsduringrituximabtreatment
_version_ 1721235941920604160

Similar Items